Feature | November 08, 2012

PFO Closure May Improve Outcomes Over Medical Therapy in Cryptogenic Stroke

Results of the RESPECT trial using the Amplatzer device presented at TCT 2012

Amplatzer Structural Heart Occulder Closure Device RESPECT Clinical Trial

November 8, 2012 — A clinical trial indicates that using an investigational medical device to close a PFO, or “hole in the heart,” may be superior to medical management alone in the prevention of a repeated stroke. Results of the RESPECT trial were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

A PFO (patent foramen ovale) is a flap-like opening between the left and right upper chambers of the heart, which typically fuses shut after birth. In approximately one in four people, the opening does not fuse shut, and in some cases, a blood clot may pass through the PFO and potentially travel to the brain, causing an ischemic stroke. It is estimated that PFO rates are three times higher in the patient population with cryptogenic stroke, or stroke without an overt source. However, to date, no randomized clinical trial has demonstrated superiority of PFO closure over standard medical therapy for secondary stroke prevention, despite there being observational data suggesting a possible benefit.

To see a video of this presentation, click here.

RESPECT was a prospective, randomized, multicenter trial designed to evaluate whether PFO closure with the Amplazter PFO Occluder is superior to the current standard medical treatment in the prevention of recurrent stroke. Made of wire mesh, the investigational device is inserted into the PFO through a catheter to seal the passageway between the left and right atria.

A total of 980 patients were enrolled over eight years. Patients diagnosed with a cryptogenic stroke and PFO (age 18-60) were randomized to either the investigational device group or the medical therapy group within 270 days of the stroke. Forty-nine percent of the patients had a large stroke as the qualifying stroke event. The average age in the study was 46, and patients were otherwise generally healthy.

Statistics from the RESPECT trial:

  • Two-year events rates were low in both the device and medically treated groups
    • 1.6 percent vs. 3 percent, respectively
    • All primary events were non-fatal, recurrent ischemic strokes
  • The clinical risk reduction of stroke using the device ranged from 46.6 percent to 72.7 percent compared to medical management alone, depending on the analysis population being assessed
    • Among the intent-to-treat analysis population, this reduction achieved borderline statistical significance
    • In per-protocol and as-treated analyses, the reductions were statistically significant
  • Serious adverse event rates did not differ between the device and medical groups
    • 23 percent vs. 21.6 percent, respectively
  • Medical therapy included one of four regimens:
    • Warfarin (25.2 percent)
    • Aspirin (46.5 percent)
    • Clopidogrel (14 percent)
    • Aspirin combined with dipyridamole (8.1 percent)
    • Aspirin combined with clopidogrel (6.3 percent)
  • The total incidence of atrial fibrillation was not significantly different between the device and medical group
    • 3 percent vs. 1.5 percent, respectively
  • No device-related thrombus, erosion or embolization was observed
  • There were no study-related deaths


“In patients between 18 and 60 years old with cryptogenic ischemic stroke and PFO, the totality of evidence from RESPECT demonstrates that PFO closure with the Amplatzer PFO Occluder provides evidence of benefit over medical management alone, with very low device and procedure-related risks,” said lead investigator John D. Carroll, M.D., co-director of the Cardiac and Vascular Center and director of interventional cardiology at the University of Colorado. “The optimal secondary prevention strategy following a cryptogenic ischemic stroke in patients who are found to have a PFO has been unknown. This need to know is particularly intense for young stroke patients who have no or minimal traditional risk factors for ischemic stroke, yet face a risk of recurrent stroke for many decades. RESPECT makes progress in both removing the 'unknown' or cryptogenic cause of some strokes and providing high quality data from a large, long-term randomized trial.”

The RESPECT clinical trial was sponsored by St. Jude Medical Inc., which provided research support to the University of Colorado School of Medicine.

For more information: www.crf.org

Related Content

ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillators (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
stress, brain activity, cardiovascular risk, PET-CT, MGH, ISSMS, The Lancet study
News | Cardiac Diagnostics| January 18, 2017
A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (ISSMS) investigators...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillators (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
University of Utah, Frank Sachse, heart failure, LVAD implantation, left ventricular assist device, biomarker, t-system

Two patients may seem equally sick based upon clinical measures, but differences in their heart physiology could predict who has the potential to recover from heart failure. A study carried out by scientists at the University of Utah finds that patients whose hearts have flattened t-tubules have a decreased chance of showing signs of recovery after implanting a mechanical heart pump. Ordinarily, t-tubules in the heart are long, thin, and rounded. Image courtesy of Frank Sachse.

News | Cardiac Diagnostics| January 17, 2017
Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
MD Buyline, James Laskaris, four medical technology innovations, very near future
Feature | Cardiac Imaging| January 17, 2017
James Laskaris, emerging technology analyst at MD Buyline, recently offered his perspective on new medical technology...
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
Overlay Init